All clinical trial data and research results presented on this page are from peer-reviewed scientific journals and official publications
In the Falutz 2010 trials, once-daily dosing at 2 mg produced mean IGF-1 increases that normalized toward baseline over the 26-week trial, suggesting some receptor adaptation without complete desensitization
This accelerated synthesis means faster recovery from training and more efficient conversion of dietary protein into muscle tissue
Its worth noting, however, that these results might not apply to ipamorelin, as these two very similar peptides are not identical
By supporting your own growth hormone and IGF-1, this combination is associated in research and clinical use with a broad set of benefits: Keep expectations grounded: these are research-supported possibilities, not guarantees, and individual results vary with your physiology, training, nutrition, and consistency